BIOMAT Database Logo BIOMAT Database Logo

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply. 2023

Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
IRCCS Bambino Gesù Children's Hospital, Rome, Italy franco.locatelli@opbg.net.

UI MeSH Term Description Entries

Related Publications

Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
June 2023, The New England journal of medicine,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.
February 2015, Pediatric hematology and oncology,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
March 2021, Cancers,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience.
January 2024, Practical radiation oncology,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
November 2020, Nature medicine,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
June 2023, Nature medicine,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
November 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
January 2024, Nature medicine,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
February 2022, Biomolecules,
Concetta Quintarelli, and Francesca Del Bufalo, and Franco Locatelli
Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
May 2016, The Annals of pharmacotherapy,
Copied contents to your clipboard!